Among our cohort of 36 patients, we analyzed 12 melanoma patients (4 BRAF V600+ and 8 BRAF V600−) for which matched pre-therapy and post-therapy biopsies were available, to identify potential genetic predictors of intrinsic and/or acquired resistance (Supplementary Figure S4). Here, BRAF is linked to melanoma.